Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 2276 - 2300 of 15269 in total

Belantamab mafodotin

Belantamab mafodotin, or GSK2857916, is an afucosylated monoclonal antibody that targets B cell maturation antigen conjugated to the microtubule disrupter monomethyl auristatin-F (MMAF). Belantamab mafodotin was granted FDA accelerated approval on 5 August 2020 for the treatment of multiple myeloma; however, its manufacturer began the process for withdrawal of the...
Approved
Matched Description: … In the meantime, belantamab mafodotin will be available for patients in the Risk Evaluation and Mitigation …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Vasopressin

Vasopressin (arginine-vasopressin or antidiuretic hormone) is a nonapeptide primarily produced in the hypothalamus that exhibits diverse physiological functions related to diuresis, hemodynamic modulation, and behaviour.[A110, A111, A112, A113, A228008] Vasopressin is very similar to oxytocin, differing in the third and eighth amino acids. Despite a wide variety of functions, exogenous...
Approved
Matched Description: … renal fluid reuptake by acting through V1 and V2 cellular receptors. ... [A110, A111, A112, A113, A228008] Vasopressin is very similar to oxytocin, differing in the third and ... hypothalamus that exhibits diverse physiological functions related to diuresis, hemodynamic modulation, and …
Matched Categories: … Vasopressin and Analogues ... Amino Acids, Peptides, and Proteins ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Iron protein succinylate

Approved
Investigational
Matched Categories: … Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …

Anifrolumab

Anifrolumab, or MEDI-546, is a type 1 interferon receptor (IFNAR) inhibiting IgG1κ monoclonal antibody indicated in the treatment of adults with moderate to severe systemic lupus erythematosus.[A237074,L34929] The standard therapy for systemic lupus erythematosus consists of antimalarials like hydroxychloroquine, glucocorticoids like dexamethasone, and disease modifying antirheumatic drugs like methotrexate.[A237079,L34929] Three...
Approved
Investigational
Matched Description: … [A237079,L34929] Three monoclonal antibodies (anifrolumab, [rontalizumab], and [sifalimumab]) that ... erythematosus consists of antimalarials like [hydroxychloroquine], glucocorticoids like [dexamethasone], and ... placebo groups; and patient populations were largely homogenous, which may have increased the odds of …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Protein hydrolysate

Approved
Matched Categories: … Amino Acids, Peptides, and Proteins …

Tropicamide

Tropicamide is an alkaloid atropine‐derived anticholinergic drug and a non‐selective antagonist of muscarinic acetylcholine (mACh) receptors. Usually available in ophthalmic formulations, tropicamide is used to cause mydriasis and cycloplegia for eye exams or ocular procedures. It is also used in combination with hydroxyamphetamine for the same indication. Oral tropicamide has...
Approved
Investigational
Matched Description: … Tropicamide is an alkaloid atropine‐derived anticholinergic drug and a non‐selective antagonist of muscarinic ... [A230103] Usually available in ophthalmic formulations, tropicamide is used to cause mydriasis and cycloplegia …
Matched Categories: … Mydriatics and Cycloplegics …

Spesolimab

Spesolimab is an interleukin-36 (IL-36) receptor antagonist. It is a humanized monoclonal immunoglobulin G1 antibody that was produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology. The biosimilar of the drug, spesolimab-sbzo, was first approved by the FDA in September 2022 to treat generalized pustular psoriasis flares. Spesolimab...
Approved
Investigational
Matched Description: … works by inhibiting the inflammatory signaling pathway of IL-36,[L43090] which is often overexpressed and ... Committee for Medicinal Products for Human Use (CHMP) to be granted marketing authorization in October 2022 and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Delavirdine

A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.
Approved
Matched Categories: … Nucleic Acid Synthesis Inhibitors …

Propyl alcohol

A colorless liquid made by oxidation of aliphatic hydrocarbons that is used as a solvent and chemical intermediate.
Approved
Matched Description: … A colorless liquid made by oxidation of aliphatic hydrocarbons that is used as a solvent and chemical …
Matched Categories: … Antiseptics and Disinfectants …

Necitumumab

Necitumumab is an intravenously administered recombinant monoclonal IgG1 antibody used in the treatment of non-small cell lung cancer (NSCLC) as an EGFR antagonist. It functions by binding to epidermal growth factor receptor (EGFR) and prevents binding of its ligands, a process that is involved in cell proliferation, metastasis, angiogenesis, and...
Approved
Investigational
Matched Description: … It functions by binding to epidermal growth factor receptor (EGFR) and prevents binding of its ligands ... , a process that is involved in cell proliferation, metastasis, angiogenesis, and malignant progression ... Necitumumab is approved for use in combination with cisplatin and gemcitabine as a first-line treatment …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Inulin

A starch found in the tubers and roots of many plants. Since it is hydrolyzable to fructose, it is classified as a fructosan. It has been used in physiologic investigation for determination of the rate of glomerular function.
Approved
Investigational
Nutraceutical
Matched Description: … A starch found in the tubers and roots of many plants. …
Matched Categories: … inulin and other polyfructosans ... Tests for Renal Function and Ureteral Injuries …

Gentian violet cation

A dye that is a mixture of violet rosanilinis with antibacterial, antifungal, and anthelmintic properties.
Approved
Matched Description: … A dye that is a mixture of violet rosanilinis with antibacterial, antifungal, and anthelmintic properties …
Matched Categories: … Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …

Aprotinin

Aprotinin is a protein-based drug that is also known as bovine pancreatic trypsin inhibitor (BPTI). Since it demonstrates the capacity to slow fibrinolysis, it has been employed to reduce bleeding during complex surgery such as heart and liver surgery. For this use, it is typically administered by injection. The goal...
Approved
Investigational
Withdrawn
Matched Description: … to slow fibrinolysis, it has been employed to reduce bleeding during complex surgery such as heart and ... was subsequently to minimize end-organ damage resulting from hypotension due to blood loss in surgery and …
Matched Categories: … Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …

Tocainide

An antiarrhythmic agent which exerts a potential- and frequency-dependent block of sodium channels.
Approved
Matched Description: … An antiarrhythmic agent which exerts a potential- and frequency-dependent block of sodium channels. …

Trametinib

Trametinib is an orally bioavailable mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 inhibitor.[A258298,A258293] It was first approved by the FDA in May 2013 for the treatment of melanoma. It was later approved by Health Canada on July 18, 2013 and by the European Commission on June 30, 2014. Trametinib...
Approved
Matched Description: … Trametinib is an orally bioavailable mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and ... [A258298] It was later approved by Health Canada on July 18, 2013 [L45588] and by the European Commission ... currently approved to treat a variety of cancers with BRAF mutations, such as non-small cell lung cancer and …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Afatinib

Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif [FDA Label]. For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations...
Approved
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Teplizumab

Teplizumab (teplizumab-mzwv) is a humanized IgG1 kappa CD3-directed monoclonal antibody used to delay the onset of type 1 diabetes (T1D).[A241480,A241045,A241475,L44091] T1D is an autoimmune condition in which T cell-mediated destruction of pancreatic β cells leads to loss of insulin production, impaired glycemic control, and reliance on exogenous insulin. Anti-CD3 therapy...
Approved
Investigational
Matched Description: … L44091] Fc-receptors can bind to the "tail-end" anti-CD3 antibodies in an antigen-non-specific manner and ... cell-mediated destruction of pancreatic β cells leads to loss of insulin production, impaired glycemic control, and ... mechanism of action of teplizumab has not been fully elucidated, it may involve partial agonistic signaling and …
Matched Categories: … Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins …

Regdanvimab

Regdanvimab (CT-P59) is a recombinant human IgG1 monoclonal antibody directed at the receptor binding domain (RBD) of the SARS-CoV-2 spike protein. It blocks the interaction between viral spike proteins and angiotensin-converting enzyme 2 (ACE2) that allows for viral entry into the cell, thereby inhibiting the virus' ability to replicate. Trials...
Approved
Investigational
Matched Description: … [L39140] It blocks the interaction between viral spike proteins and angiotensin-converting enzyme 2 ( …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Immune Sera and Immunoglobulins …

Darbepoetin alfa

Human erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD). Produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.
Approved
Investigational
Matched Categories: … Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …

Dulaglutide

Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA in 2014, and...
Approved
Investigational
Matched Description: … agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and ... [A236070] Dulaglutide was initially approved by the FDA in 2014, and in February 2020 was approved for ... use in patients with T2DM and multiple cardiovascular risk factors for the prevention of cardiovascular …
Matched Categories: … Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Blinatumomab

Blinatumomab is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody formed by the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and an anti-CD19 scFV through a short peptide linker.[A254836,L44311] CD3 is an antigen expressed on the surface of T-cells, while CD19 is mostly expressed on the surface of...
Approved
Investigational
Matched Description: … promotes tumor cell lysis and apoptosis. ... monoclonal antibody formed by the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and ... blinatumomab has an affinity to both antigens, it redirects T-cells to tumor cells expressing CD19 and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Artenimol

Artenimol is an artemisinin derivative and antimalarial agent used in the treatment of uncomplicated Plasmodium falciparum infections [FDA Label]. It was first authorized for market by the European Medicines Agency in October 2011 in combination with DB13941 as the product Eurartesim. Artemisinin combination therapy is highly effective against malaria and...
Approved
Experimental
Investigational
Matched Description: … Artenimol is an artemisinin derivative and antimalarial agent used in the treatment of uncomplicated ... Artemisinin combination therapy is highly effective against malaria and stongly recommended by the World …
Matched Categories: … Artemisinin and derivatives ... artenimol and piperaquine ... Antiparasitic Products, Insecticides and Repellents …

Dihydralazine

Dihydralazine is under investigation in clinical trial NCT00311974 (The Effect of Dihydralazine on Kidney Function and Hormones in Healthy Individuals).
Approved
Experimental
Matched Description: … is under investigation in clinical trial NCT00311974 (The Effect of Dihydralazine on Kidney Function and …
Matched Categories: … dihydralazine and diuretics ... Hydrazinophthalazine Derivatives and Diuretics ... dihydralazine and diuretics, combinations with other drugs …

Enfortumab vedotin

Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protease-cleavable link. It is similar to brentuximab vedotin, another...
Approved
Investigational
Matched Description: … clinical development of enfortumab vedotin was the result of a collaboration between Astellas Pharma and ... Seattle Genetics [A188868] and it was first approved for use in the United States in December 2019 under ... [L10836] It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Eftrenonacog alfa

Eftrenonacog alfa is a long-acting recombinant fusion protein used in the treatment of hemophilia B. It is comprised of a single molecule of human factor IX (FIX) covalently linked to the constant region (Fc) domain of human IgG1 via recombinant DNA technology in a human embryonic kidney cell line (HEK293H)...
Approved
Investigational
Matched Description: … It was first approved by the FDA in March 2014 and later approved by the EMA in May 2016. ... Eftrenonacog alfa was developed and marketed as Alprolix for intravenous injection by Biogen. ... blood disorder with an incidence of approximately once every 30,000 male births in all populations and …
Matched Categories: … Enzymes and Coenzymes ... Amino Acids, Peptides, and Proteins …
Displaying drugs 2276 - 2300 of 15269 in total